Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Outlook:
Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market size was over USD 8.28 billion in 2025 and is anticipated to cross USD 13.23 billion by 2035, witnessing more than 4.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 8.64 billion.
The growth of the market can be attributed to the increasing geriatric population and the rising prevalence of non-metastatic castration-resistant prostate cancer amongst individuals on a global level. People above 50 have a higher chance to be diagnosed with nmCRPC, therefore, the surge in the geriatric population is anticipated to be one of the major growth factors of the market. According to the data collected by the National Cancer Institute of the U.S. Department of Health and Human Services, in 2020, the estimated new cases and the number of deaths from prostate cancer in the U.S. were 191,930 and 33,330, respectively.
In addition to these, global non-metastatic castration resistant prostate cancer (NMcrpc) market trends such as Extensive research associated with cancer treatment in western countries, along with the growing investment in the development of advanced therapies are expected to fuel the progress of the market during the forecast period. People nowadays are more aware of early diagnosis of cancer owing to the surge in awareness and launch of the various government program to promote the treatment of cancer. For instance, in India government programs such as Health Minister’s Cancer Patient Fund, National Health Protection Scheme, and others are observed to be quite beneficial to get cancer treatment. Hence, all these factors are anticipated to influence the market growth over the forecast period.
